210 related articles for article (PubMed ID: 27161641)
1. Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB.
Schuster S; Vavra M; Kern WV
Antimicrob Agents Chemother; 2016 Jul; 60(7):4315-23. PubMed ID: 27161641
[TBL] [Abstract][Full Text] [Related]
2. Efflux-Mediated Resistance to New Oxazolidinones and Pleuromutilin Derivatives in Escherichia coli with Class Specificities in the Resistance-Nodulation-Cell Division-Type Drug Transport Pathways.
Schuster S; Vavra M; Kern WV
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209014
[TBL] [Abstract][Full Text] [Related]
3. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
[TBL] [Abstract][Full Text] [Related]
4. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Bohnert JA; Schuster S; Fähnrich E; Trittler R; Kern WV
J Antimicrob Chemother; 2007 Jun; 59(6):1216-22. PubMed ID: 17062614
[TBL] [Abstract][Full Text] [Related]
5. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
[TBL] [Abstract][Full Text] [Related]
7. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
[TBL] [Abstract][Full Text] [Related]
8. Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB.
Bohnert JA; Schuster S; Seeger MA; Fähnrich E; Pos KM; Kern WV
J Bacteriol; 2008 Dec; 190(24):8225-9. PubMed ID: 18849422
[TBL] [Abstract][Full Text] [Related]
9. Multiple entry pathways within the efflux transporter AcrB contribute to multidrug recognition.
Zwama M; Yamasaki S; Nakashima R; Sakurai K; Nishino K; Yamaguchi A
Nat Commun; 2018 Jan; 9(1):124. PubMed ID: 29317622
[TBL] [Abstract][Full Text] [Related]
10. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.
Blair JM; Bavro VN; Ricci V; Modi N; Cacciotto P; Kleinekathӧfer U; Ruggerone P; Vargiu AV; Baylay AJ; Smith HE; Brandon Y; Galloway D; Piddock LJ
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3511-6. PubMed ID: 25737552
[TBL] [Abstract][Full Text] [Related]
11. New Topoisomerase Inhibitors: Evaluating the Potency of Gepotidacin and Zoliflodacin in Fluoroquinolone-Resistant Escherichia coli upon
Schuster S; Vavra M; Köser R; Rossen JWA; Kern WV
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199388
[TBL] [Abstract][Full Text] [Related]
12. Perturbed structural dynamics underlie inhibition and altered efflux of the multidrug resistance pump AcrB.
Reading E; Ahdash Z; Fais C; Ricci V; Wang-Kan X; Grimsey E; Stone J; Malloci G; Lau AM; Findlay H; Konijnenberg A; Booth PJ; Ruggerone P; Vargiu AV; Piddock LJV; Politis A
Nat Commun; 2020 Nov; 11(1):5565. PubMed ID: 33149158
[TBL] [Abstract][Full Text] [Related]
13. Effect of site-directed mutations in multidrug efflux pump AcrB examined by quantitative efflux assays.
Kinana AD; Vargiu AV; Nikaido H
Biochem Biophys Res Commun; 2016 Nov; 480(4):552-557. PubMed ID: 27789287
[TBL] [Abstract][Full Text] [Related]
14. Resistance in Escherichia coli: variable contribution of efflux pumps with respect to different fluoroquinolones.
Huguet A; Pensec J; Soumet C
J Appl Microbiol; 2013 May; 114(5):1294-9. PubMed ID: 23414263
[TBL] [Abstract][Full Text] [Related]
15. Proximal Binding Pocket Arg717 Substitutions in Escherichia coli AcrB Cause Clinically Relevant Divergencies in Resistance Profiles.
Zwama M; Nishino K
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239221. PubMed ID: 35311521
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
Mowla R; Wang Y; Ma S; Venter H
Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
[TBL] [Abstract][Full Text] [Related]
17. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
Schuster S; Vavra M; Wirth DAN; Kern WV
Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
[TBL] [Abstract][Full Text] [Related]
18. Site-directed disulfide cross-linking shows that cleft flexibility in the periplasmic domain is needed for the multidrug efflux pump AcrB of Escherichia coli.
Takatsuka Y; Nikaido H
J Bacteriol; 2007 Dec; 189(23):8677-84. PubMed ID: 17905989
[TBL] [Abstract][Full Text] [Related]
19. A fluorescent microplate assay quantifies bacterial efflux and demonstrates two distinct compound binding sites in AcrB.
Iyer R; Ferrari A; Rijnbrand R; Erwin AL
Antimicrob Agents Chemother; 2015 Apr; 59(4):2388-97. PubMed ID: 25645845
[TBL] [Abstract][Full Text] [Related]
20. Unidirectional peristaltic movement in multisite drug binding pockets of AcrB from molecular dynamics simulations.
Feng Z; Hou T; Li Y
Mol Biosyst; 2012 Oct; 8(10):2699-709. PubMed ID: 22825052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
